Status:
UNKNOWN
H7HLAII DNA Influenza Vaccine
Lead Sponsor:
Oslo University Hospital
Conditions:
Influenza A
Pandemic Influenza
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess safety and immunogenicity of H7HLAII, a DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing hu...
Detailed Description
H7HLAII is a DNA vaccine that could remedy the current challenges of slow production for conventional influenza vaccines. The prolonged production time of current influenza vaccines has as a consequen...
Eligibility Criteria
Inclusion
- Healthy subjects, as concluded from the medical history, physical examination test including normal vital signs, and clinical judgment, without the need for medication.
- For women with childbearing potential (WOCBP), defined as fertile following menarche and until becoming post-menopausal (i.e. no menses for 12 months without an alternative medical cause) unless permanently sterile by hysterectomy, bilateral salpingectomy and bilateral oophorectomy: Must use a highly effective contraceptive measures (from 4 weeks prior to the first vaccination until 4 weeks after the second vaccination), and a negative urine pregnancy test before administration of each dose of vaccine. Must agree to not donate eggs during the study and the first three months after their last study visit.
- Able to understand and willing to sign the Informed Consent Form (ICF), which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- Subjects able to understand and comply with the study protocol, including being able to attend the scheduled visits.
Exclusion
- Medical Conditions
- Ongoing or recent (\< 2 weeks) intercurrent febrile condition
- Previous reports of autoimmune disease
- Concurrent chronic active viral hepatitis B or C or HIV
- BMI\>30
- Persons with a history of anaphylaxis or serious reactions to a prior vaccination
- Persons with known hypersensitivity to any of the vaccine components
- Persons who have had a temperature \>38 °C during the previous 72 hours
- Persons who have had an acute respiratory infection during the last 7 days
- Persons who have abnormal electrocardiogram (ECG)
- Women who are pregnant or breast-feeding (women of child-bearing potential must have a negative pregnancy test at screening)
- Have received any vaccination within the last month
- Prior/Concomitant Therapy 12. Currently taking anti-inflammatory or immunosuppressive drugs 13. Currently taking antibiotics, steroids, phenytoin, chemotherapy, or other immunosuppressive drugs
- Prior/Concurrent Clinical Study Experience 14. Persons who have participated in another clinical trial during the last month
- Diagnostic assessments 15. Abnormal values of the hematologic and clinical chemistry parameters, as judged by the Investigator, including creatinine, AST, ALT (SGPT), bilirubin and alkaline phosphatase values above normal reference values 16. Positive autoantibodies (anti-nuclear antigens, rheumatoid factor) 17. Serum IgG and IgM lower or higher than the normal reference levels 18. Positive serology tests for hepatitis B or C with detectable hepatitis B HBsAg or DNA, or hepatitis C RNA 19. Positive HIV serology test
Key Trial Info
Start Date :
July 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT06046092
Start Date
July 15 2023
End Date
December 31 2024
Last Update
September 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital
Oslo, Norway, 0372